Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Shares Outstanding (Weighted Average) (2021 - 2025)

Bioregenx has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $959.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 5.19% year-over-year to $959.7 million; the TTM value through Dec 2025 reached $959.7 million, up 5.19%, while the annual FY2025 figure was $959.7 million, 5.19% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $959.7 million at Bioregenx, roughly flat from $960.9 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $960.9 million in Q3 2025 and troughed at $269.7 million in Q4 2021.
  • A 5-year average of $670.3 million and a median of $764.3 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): changed 0.0% in 2022 and later surged 183.34% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $269.7 million in 2021, then changed by 0.0% to $269.7 million in 2022, then soared by 137.18% to $639.8 million in 2023, then skyrocketed by 42.61% to $912.4 million in 2024, then increased by 5.19% to $959.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BRGX at $959.7 million in Q4 2025, $960.9 million in Q3 2025, and $959.2 million in Q2 2025.